WO2007084391A2 - Thiazole compounds as protein kinase b ( pkb) inhibitors - Google Patents
Thiazole compounds as protein kinase b ( pkb) inhibitors Download PDFInfo
- Publication number
- WO2007084391A2 WO2007084391A2 PCT/US2007/000871 US2007000871W WO2007084391A2 WO 2007084391 A2 WO2007084391 A2 WO 2007084391A2 US 2007000871 W US2007000871 W US 2007000871W WO 2007084391 A2 WO2007084391 A2 WO 2007084391A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- alkyl
- thiazol
- compound
- phenyl
- Prior art date
Links
- 0 **c1nc(*)c(*)[s]1 Chemical compound **c1nc(*)c(*)[s]1 0.000 description 9
- AZGNJBCTWPTNRB-FQEVSTJZSA-N C=C([C@H](Cc1ccc(C(F)(F)F)cc1)N)Nc1ncc(-c(cc2)cc3c2cncc3)[s]1 Chemical compound C=C([C@H](Cc1ccc(C(F)(F)F)cc1)N)Nc1ncc(-c(cc2)cc3c2cncc3)[s]1 AZGNJBCTWPTNRB-FQEVSTJZSA-N 0.000 description 1
- DJSLXUBBYQZYAQ-UHFFFAOYSA-N C=CC(C=C1)=CC#CC1N Chemical compound C=CC(C=C1)=CC#CC1N DJSLXUBBYQZYAQ-UHFFFAOYSA-N 0.000 description 1
- NXKNUYSLWVDVCI-UHFFFAOYSA-N CC(C)(C)OC(N(C)c1ncc(ccc(B2OC(C)(C)C(C)(C)O2)c2)c2c1)=O Chemical compound CC(C)(C)OC(N(C)c1ncc(ccc(B2OC(C)(C)C(C)(C)O2)c2)c2c1)=O NXKNUYSLWVDVCI-UHFFFAOYSA-N 0.000 description 1
- CPCYZUREFGOQLR-VWLOTQADSA-N CC(C)(C)OC([N]([C@@H](Cc1ccc(C(F)(F)F)cc1)C1)(C(OC(C)(C)C)=O)N1c1nc(C=O)c(-c2cc3ccncc3cc2)[s]1)=O Chemical compound CC(C)(C)OC([N]([C@@H](Cc1ccc(C(F)(F)F)cc1)C1)(C(OC(C)(C)C)=O)N1c1nc(C=O)c(-c2cc3ccncc3cc2)[s]1)=O CPCYZUREFGOQLR-VWLOTQADSA-N 0.000 description 1
- OHOISSWDLIHJIZ-MHTVFEQDSA-N CC(C1)C(NC(C2)=O)=C2C=C1c1cnc(NC[C@H](Cc2cc(O)c(C(F)(F)F)cc2)N)[s]1 Chemical compound CC(C1)C(NC(C2)=O)=C2C=C1c1cnc(NC[C@H](Cc2cc(O)c(C(F)(F)F)cc2)N)[s]1 OHOISSWDLIHJIZ-MHTVFEQDSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- OJKWMGJCGNSSQQ-HACHORDNSA-N CC1C=CC=CC1[C@H](COC1=O)N1I Chemical compound CC1C=CC=CC1[C@H](COC1=O)N1I OJKWMGJCGNSSQQ-HACHORDNSA-N 0.000 description 1
- DVINWYFPNRZXBA-UHFFFAOYSA-N CCCCC(C=C1)=CC#CC1N Chemical compound CCCCC(C=C1)=CC#CC1N DVINWYFPNRZXBA-UHFFFAOYSA-N 0.000 description 1
- CUHWZEWMVILNLV-UHFFFAOYSA-N CCOCc1c(-c2nc(ccnc3)c3[s]2)[s]c(N)n1 Chemical compound CCOCc1c(-c2nc(ccnc3)c3[s]2)[s]c(N)n1 CUHWZEWMVILNLV-UHFFFAOYSA-N 0.000 description 1
- LSANDVOQPROLCN-IBGZPJMESA-N CNc1cc(cc(cc2)-c3cnc(NC[C@H](Cc(cc4)ccc4Cl)N)[s]3)c2cn1 Chemical compound CNc1cc(cc(cc2)-c3cnc(NC[C@H](Cc(cc4)ccc4Cl)N)[s]3)c2cn1 LSANDVOQPROLCN-IBGZPJMESA-N 0.000 description 1
- QNPXGYWAPZLUDI-AWEZNQCLSA-N COCc1c(-c2nc3ccncc3[s]2)[s]c(NC[C@H](Cc2ccc(C(F)(F)F)cc2)N)n1 Chemical compound COCc1c(-c2nc3ccncc3[s]2)[s]c(NC[C@H](Cc2ccc(C(F)(F)F)cc2)N)n1 QNPXGYWAPZLUDI-AWEZNQCLSA-N 0.000 description 1
- UZNKGLMJMNTJJW-UHFFFAOYSA-N COc(ccc(CC(CNc1ncc(-c(cc2C3)ccc2NC3=O)[s]1)N)c1)c1F Chemical compound COc(ccc(CC(CNc1ncc(-c(cc2C3)ccc2NC3=O)[s]1)N)c1)c1F UZNKGLMJMNTJJW-UHFFFAOYSA-N 0.000 description 1
- YRJNCXKCWFWNFA-UHFFFAOYSA-N COc1ccc(CC(CNc2ncc(-c3ccc(cncc4)c4c3)[s]2)N)cc1F Chemical compound COc1ccc(CC(CNc2ncc(-c3ccc(cncc4)c4c3)[s]2)N)cc1F YRJNCXKCWFWNFA-UHFFFAOYSA-N 0.000 description 1
- IHRXKEJDNJYGGA-LBTNJELSSA-N C[C@H]([C@@H](C)c1ccc(C(F)(F)F)cc1)C(N([C@@H](CO1)c2ccccc2)C1=O)=O Chemical compound C[C@H]([C@@H](C)c1ccc(C(F)(F)F)cc1)C(N([C@@H](CO1)c2ccccc2)C1=O)=O IHRXKEJDNJYGGA-LBTNJELSSA-N 0.000 description 1
- FKTJYHMIUIBGBT-APPDUMDISA-N C[C@H]([C@@H](CNc1ncc(-c(cc2F)cc(C3)c2NC3=O)[s]1)N)c1ccc(C(F)(F)F)cc1 Chemical compound C[C@H]([C@@H](CNc1ncc(-c(cc2F)cc(C3)c2NC3=O)[s]1)N)c1ccc(C(F)(F)F)cc1 FKTJYHMIUIBGBT-APPDUMDISA-N 0.000 description 1
- RVDVOVCNUIJLKZ-WJDWOHSUSA-N Cc(cc(C/C(/N)=C/NC1SC(c(cc2)cc(N3C)c2NC3=O)=CN1C)cc1)c1Cl Chemical compound Cc(cc(C/C(/N)=C/NC1SC(c(cc2)cc(N3C)c2NC3=O)=CN1C)cc1)c1Cl RVDVOVCNUIJLKZ-WJDWOHSUSA-N 0.000 description 1
- UFCFTDIPQQTTNA-UHFFFAOYSA-N Cc1cc2ccncc2[s]1 Chemical compound Cc1cc2ccncc2[s]1 UFCFTDIPQQTTNA-UHFFFAOYSA-N 0.000 description 1
- NTPKGMUVGJRKBM-UHFFFAOYSA-N Cc1nc2ccncc2[s]1 Chemical compound Cc1nc2ccncc2[s]1 NTPKGMUVGJRKBM-UHFFFAOYSA-N 0.000 description 1
- KBLFGUDFYGRBIB-UHFFFAOYSA-N NC(Cc(cc1)ccc1OC(F)(F)F)CNc1ncc(-c2cc3ccncc3cc2)[s]1 Chemical compound NC(Cc(cc1)ccc1OC(F)(F)F)CNc1ncc(-c2cc3ccncc3cc2)[s]1 KBLFGUDFYGRBIB-UHFFFAOYSA-N 0.000 description 1
- GHHABNVYGZLMRP-UHFFFAOYSA-N NC(Cc1ccc(C(F)(F)F)cc1F)CNc1ncc(-c(cc2)cc3c2cncc3)[s]1 Chemical compound NC(Cc1ccc(C(F)(F)F)cc1F)CNc1ncc(-c(cc2)cc3c2cncc3)[s]1 GHHABNVYGZLMRP-UHFFFAOYSA-N 0.000 description 1
- XXIWNSJANUWTAF-AWEZNQCLSA-N N[C@@H](Cc1c[nH]c2ccccc12)CNc1ncc(-c(cc2)cc(S3)c2NC3=O)[s]1 Chemical compound N[C@@H](Cc1c[nH]c2ccccc12)CNc1ncc(-c(cc2)cc(S3)c2NC3=O)[s]1 XXIWNSJANUWTAF-AWEZNQCLSA-N 0.000 description 1
- OQSWTHOOFMVYCO-AWEZNQCLSA-N N[C@@H](Cc1cc(C(F)(F)F)ccc1)CNc1ncc(-c(cc2)cc(O3)c2NC3=O)[s]1 Chemical compound N[C@@H](Cc1cc(C(F)(F)F)ccc1)CNc1ncc(-c(cc2)cc(O3)c2NC3=O)[s]1 OQSWTHOOFMVYCO-AWEZNQCLSA-N 0.000 description 1
- KRMQYMGMTJUCME-AWEZNQCLSA-N N[C@@H](Cc1ccc(C(F)(F)F)c(F)c1)CNc1ncc(-c(cc2)cc(C3)c2NC3=O)[s]1 Chemical compound N[C@@H](Cc1ccc(C(F)(F)F)c(F)c1)CNc1ncc(-c(cc2)cc(C3)c2NC3=O)[s]1 KRMQYMGMTJUCME-AWEZNQCLSA-N 0.000 description 1
- YAFFUBXKKWHFEZ-FQEVSTJZSA-N N[C@@H](Cc1ccc(C(F)(F)F)cc1)CNc1nc(-c2cnc[o]2)c(-c2cc3ccncc3cc2)[s]1 Chemical compound N[C@@H](Cc1ccc(C(F)(F)F)cc1)CNc1nc(-c2cnc[o]2)c(-c2cc3ccncc3cc2)[s]1 YAFFUBXKKWHFEZ-FQEVSTJZSA-N 0.000 description 1
- JQESGUJJLSQMQR-ZZDYIDRTSA-N N[C@@H](Cc1ccc(C(F)(F)F)cc1)CNc1nc(C#CC2(C=CCC2)O)c(-c(cc2)cc3c2cncc3)[s]1 Chemical compound N[C@@H](Cc1ccc(C(F)(F)F)cc1)CNc1nc(C#CC2(C=CCC2)O)c(-c(cc2)cc3c2cncc3)[s]1 JQESGUJJLSQMQR-ZZDYIDRTSA-N 0.000 description 1
- FXEOSILTNYQUAX-PVCZSOGJSA-N N[C@@H](Cc1ccc(C(F)(F)F)cc1)CNc1nc(C(CO)(F)F)c(-c(cc2)cc3c2NC(O)O3)[s]1 Chemical compound N[C@@H](Cc1ccc(C(F)(F)F)cc1)CNc1nc(C(CO)(F)F)c(-c(cc2)cc3c2NC(O)O3)[s]1 FXEOSILTNYQUAX-PVCZSOGJSA-N 0.000 description 1
- CMUKDYXRDCIXHJ-INIZCTEOSA-N N[C@@H](Cc1ccc(C(F)(F)F)cc1)CNc1ncc(-c(cc2)cc(C#N)c2F)[s]1 Chemical compound N[C@@H](Cc1ccc(C(F)(F)F)cc1)CNc1ncc(-c(cc2)cc(C#N)c2F)[s]1 CMUKDYXRDCIXHJ-INIZCTEOSA-N 0.000 description 1
- OLXOCLWPQPPADC-AWEZNQCLSA-N N[C@@H](Cc1cccc(Cl)c1)CNc1nc(COCC(F)(F)F)c(-c2nc3ccncc3[s]2)[s]1 Chemical compound N[C@@H](Cc1cccc(Cl)c1)CNc1nc(COCC(F)(F)F)c(-c2nc3ccncc3[s]2)[s]1 OLXOCLWPQPPADC-AWEZNQCLSA-N 0.000 description 1
- QWCRSSNILAZCCN-UHFFFAOYSA-N Nc1cc(cc(cc2)Br)c2c(Br)n1 Chemical compound Nc1cc(cc(cc2)Br)c2c(Br)n1 QWCRSSNILAZCCN-UHFFFAOYSA-N 0.000 description 1
- PQKLBIXLXFRNKT-UHFFFAOYSA-N Nc1cc(cc(cc2)Br)c2cn1 Chemical compound Nc1cc(cc(cc2)Br)c2cn1 PQKLBIXLXFRNKT-UHFFFAOYSA-N 0.000 description 1
- RIYDEYWRFIHXBD-ZZXKWVIFSA-N O=C(/C=C/c1ccc(C(F)(F)F)cc1)Cl Chemical compound O=C(/C=C/c1ccc(C(F)(F)F)cc1)Cl RIYDEYWRFIHXBD-ZZXKWVIFSA-N 0.000 description 1
- ANRMAUMHJREENI-ZZXKWVIFSA-N OC(/C=C/c1ccc(C(F)(F)F)cc1)=O Chemical compound OC(/C=C/c1ccc(C(F)(F)F)cc1)=O ANRMAUMHJREENI-ZZXKWVIFSA-N 0.000 description 1
- BZPONHAJAYUWHX-BDPFGBAYSA-N OC(/C=C/c1ccc(C(F)(F)F)cc1)N([C@@H](CO1)c2ccccc2)C1=O Chemical compound OC(/C=C/c1ccc(C(F)(F)F)cc1)N([C@@H](CO1)c2ccccc2)C1=O BZPONHAJAYUWHX-BDPFGBAYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES07718125T ES2389062T3 (es) | 2006-01-18 | 2007-01-11 | Compuestos de tiazol como inhibidores de proteína cinasa B (PKB) |
AU2007207743A AU2007207743B2 (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase B (PKB) inhibitors |
EA200801716A EA200801716A1 (ru) | 2006-01-18 | 2007-01-11 | Тиазольные соединения и их применение |
EP07718125A EP1981884B1 (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase b (pkb) inhibitors |
BRPI0706621-0A BRPI0706621A2 (pt) | 2006-01-18 | 2007-01-11 | composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto |
JP2008551297A JP5199885B2 (ja) | 2006-01-18 | 2007-01-11 | プロテインキナーゼb(pkb)阻害剤としてのチアゾール化合物 |
CA2636077A CA2636077C (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase b (pkb) inhibitors |
IL192751A IL192751A0 (en) | 2006-01-18 | 2008-07-10 | Thiazole compounds as protein kinase b (pkb) inhibitors |
NO20083572A NO20083572L (no) | 2006-01-18 | 2008-08-18 | Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75954606P | 2006-01-18 | 2006-01-18 | |
US60/759,546 | 2006-01-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007084391A2 true WO2007084391A2 (en) | 2007-07-26 |
WO2007084391A3 WO2007084391A3 (en) | 2008-03-20 |
Family
ID=38180602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/000871 WO2007084391A2 (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase b ( pkb) inhibitors |
Country Status (21)
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008100456A2 (en) * | 2007-02-13 | 2008-08-21 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
WO2009011880A2 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
WO2009137391A3 (en) * | 2008-05-06 | 2009-12-30 | Smithkline Beecham Corporation | Benzene sulfonamide thiazole and oxazole compounds |
US7700636B2 (en) | 2004-10-18 | 2010-04-20 | Amgen Inc. | Thiadiazole compounds and methods of use |
WO2010083246A1 (en) * | 2009-01-15 | 2010-07-22 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
US7919504B2 (en) | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
WO2011044414A1 (en) * | 2009-10-08 | 2011-04-14 | Glaxosmithkline Llc | Combination |
WO2011044415A1 (en) * | 2009-10-08 | 2011-04-14 | Glaxosmithkline Llc | Combination |
WO2011046894A1 (en) * | 2009-10-12 | 2011-04-21 | Glaxosmithkline Llc | Combination |
EP2326631A2 (en) * | 2008-08-18 | 2011-06-01 | Yale University | Mif modulators |
WO2011115071A1 (ja) * | 2010-03-15 | 2011-09-22 | 国立大学法人広島大学 | チエノピリジン誘導体及びその製造方法、並びにそれを用いた有機半導体デバイス |
WO2011130921A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
US8084479B2 (en) | 2006-01-18 | 2011-12-27 | Amgen Inc. | Thiazole compounds and methods of use |
JP2013525303A (ja) * | 2010-04-16 | 2013-06-20 | アッヴィ・インコーポレイテッド | フタラジン−(2h)−オン系キナーゼ阻害薬 |
WO2013173382A1 (en) | 2012-05-15 | 2013-11-21 | Amgen Inc. | Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein |
EP2832731A4 (en) * | 2012-03-27 | 2015-08-19 | Shionogi & Co | AROMATIC HETEROCYCLIC CHAIN 5-CORE DERIVED DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY |
CN106243100A (zh) * | 2008-10-10 | 2016-12-21 | Vm生物医药公司 | 治疗酒精使用障碍,疼痛和其他疾病的药物组合与方法 |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
EP2445502B1 (en) * | 2009-06-25 | 2017-06-21 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
JP2018510857A (ja) * | 2015-03-02 | 2018-04-19 | ライジェル ファーマシューティカルズ, インコーポレイテッド | TGF−β阻害剤 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN111603466A (zh) * | 2020-06-29 | 2020-09-01 | 江南大学 | 一种乙酮类化合物在制备治疗肿瘤药物中的应用 |
CN114014787A (zh) * | 2022-01-10 | 2022-02-08 | 苏州开元民生科技股份有限公司 | 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法 |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
US11291659B2 (en) | 2017-10-05 | 2022-04-05 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US11566003B2 (en) | 2017-03-30 | 2023-01-31 | Genentech, Inc. | Isoquinolines as inhibitors of HPK1 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011525929A (ja) * | 2008-06-26 | 2011-09-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Akt活性の阻害剤 |
EP2373163B1 (en) * | 2008-12-19 | 2015-06-10 | Genentech, Inc. | Heterocyclic compounds and methods of use |
EP2440556A1 (en) * | 2009-06-10 | 2012-04-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
MY173795A (en) | 2009-11-05 | 2020-02-24 | Incozen Therapeutics Pvt Ltd | Novel benzopyran kinase modulators |
JP5578705B2 (ja) * | 2010-03-29 | 2014-08-27 | 公益財団法人相模中央化学研究所 | (アリール)ジフルオロ酢酸エステル誘導体及びその製造方法 |
WO2011133733A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
MY168757A (en) | 2011-05-04 | 2018-12-04 | Rhizen Pharmaceuticals S A | Novel compounds as modulators of protein kinases |
CA2850166C (en) | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
CN103304468A (zh) * | 2012-03-13 | 2013-09-18 | 华东师范大学 | 一种氧化吲哚的一锅法串联合成方法 |
SI3260455T1 (sl) | 2012-07-04 | 2019-07-31 | Rhizen Pharmaceuticals S.A. | Selektivni inhibitorji PI3K-delta |
MX362896B (es) | 2013-02-19 | 2019-02-22 | Amgen Inc | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. |
KR20150127249A (ko) * | 2013-03-13 | 2015-11-16 | 보스톤 바이오메디칼, 인크. | 암 치료를 위한 암 줄기세포 경로 키나아제의 저해제로서 3-(아릴 또는 헤테로아릴)메틸렌인돌린-2-온 유도체 |
WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
DK3068393T5 (da) | 2013-11-11 | 2022-08-22 | Amgen Inc | Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
EP3426652B1 (en) * | 2016-03-10 | 2021-12-01 | Astrazeneca AB | Novel inhibitors of phosphatidylinositol 3-kinase gamma |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
AU2019262589B2 (en) | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
US20220372018A1 (en) * | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
WO2021076655A1 (en) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
WO2021126816A1 (en) | 2019-12-16 | 2021-06-24 | Amgen Inc. | Dosing regimen of a kras g12c inhibitor |
CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3591600A (en) * | 1969-07-07 | 1971-07-06 | Stauffer Chemical Co | 2-aminothiazole phosphates and phosphonates |
GB1435139A (en) * | 1972-08-17 | 1976-05-12 | Sumitomo Chemical Co | Thiazole derivatives |
JPS5239827B2 (US08084479-20111227-C00023.png) | 1973-11-08 | 1977-10-07 | ||
US4086239A (en) * | 1977-07-01 | 1978-04-25 | Stauffer Chemical Company | Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods |
DK150068C (da) | 1978-06-02 | 1987-06-29 | Pfizer | Analogifremgangsmaade til fremstilling af aminothiazoler |
US4297365A (en) * | 1978-08-04 | 1981-10-27 | Ciba-Geigy Corporation | Benzimidazoles and pharmaceutical preparations containing such compounds |
US4451471A (en) * | 1981-03-18 | 1984-05-29 | Ciba-Geigy Corporation | Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same |
FR2511375A1 (fr) * | 1981-08-17 | 1983-02-18 | Rhone Poulenc Sante | Nouveaux derives de la cephalosporine, leur preparation et les medicaments qui les contiennent |
DE3630732A1 (de) * | 1986-09-10 | 1988-03-17 | Bayer Ag | 2-cyano-2-alkoximino-acetamide |
US5232921A (en) * | 1987-03-12 | 1993-08-03 | Sanofi | Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions |
JPH0753666B2 (ja) | 1987-09-14 | 1995-06-07 | 久光製薬株式会社 | 置換ジフェニルチアゾール誘導体からなる抗炎症剤 |
FR2636628B1 (fr) * | 1988-08-25 | 1990-12-28 | Sanofi Sa | Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant |
US5302608A (en) * | 1988-11-18 | 1994-04-12 | Takeda Chemical Industries, Ltd. | Age formation inhibitors |
US5145860A (en) * | 1989-01-05 | 1992-09-08 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole compounds and pharmaceutical composition comprising the same |
US5550138A (en) * | 1992-03-25 | 1996-08-27 | Takeda Chemical Industries, Ltd. | Condensed thiadiazole derivative, method of its production, and use thereof |
EP0790057B1 (en) * | 1994-11-29 | 2002-06-05 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof |
FR2735777B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
US6407124B1 (en) | 1998-06-18 | 2002-06-18 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
JP2002518380A (ja) | 1998-06-18 | 2002-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤 |
GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
AU3487500A (en) | 1999-02-08 | 2000-08-25 | Lion Bioscience Ag | Thiazole derivatives and combinatorial libraries thereof |
AUPP873799A0 (en) * | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
JP2001114690A (ja) * | 1999-08-06 | 2001-04-24 | Takeda Chem Ind Ltd | p38MAPキナーゼ阻害剤 |
EP1205478A4 (en) * | 1999-08-06 | 2004-06-30 | Takeda Chemical Industries Ltd | P38MAP KINASE INHIBITORS |
AU2001244618A1 (en) * | 2000-03-30 | 2001-10-15 | Takeda Chemical Industries Ltd. | Substituted 1,3-thiazole compounds, their production and use |
WO2001074793A2 (en) * | 2000-04-03 | 2001-10-11 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
US7074934B2 (en) * | 2000-06-13 | 2006-07-11 | Tularik Limited | Serine protease inhibitors |
GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
JP4689801B2 (ja) | 2000-08-09 | 2011-05-25 | ケミプロ化成株式会社 | アミノチアゾール誘導体の製造方法 |
JP2002053566A (ja) | 2000-08-11 | 2002-02-19 | Japan Tobacco Inc | チアゾール化合物及びその医薬用途 |
GB0114185D0 (en) * | 2001-06-12 | 2001-08-01 | Protherics Molecular Design Lt | Compounds |
US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
AR032653A1 (es) * | 2001-02-09 | 2003-11-19 | Telik Inc | Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos. |
EP1256578B1 (en) * | 2001-05-11 | 2006-01-11 | Pfizer Products Inc. | Thiazole derivatives and their use as cdk inhibitors |
WO2002100433A1 (en) * | 2001-06-11 | 2002-12-19 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
EP1760082A1 (en) * | 2001-09-28 | 2007-03-07 | Cyclacel Limited | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as anti-proliferative compounds |
GB0123589D0 (en) * | 2001-10-01 | 2001-11-21 | Syngenta Participations Ag | Organic compounds |
EP1441732A2 (en) * | 2001-11-08 | 2004-08-04 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivative and pharmaceutical use thereof |
EP1474141A1 (en) | 2002-02-13 | 2004-11-10 | Pharmagene Laboratories Ltd | 5-ht2b receptor antagonists |
WO2003072577A1 (en) | 2002-02-28 | 2003-09-04 | F.Hoffmann-La Roche Ag | Thiazole derivatives as npy receptor antagonists |
PE20030968A1 (es) * | 2002-02-28 | 2004-01-12 | Novartis Ag | Derivados de 5-feniltiazol como inhibidores de cinasas |
AU2003290507A1 (en) * | 2002-05-10 | 2004-04-08 | Cytokinetics, Inc. | Compounds, compositions and methods |
FR2842523A1 (fr) * | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
CN1688557A (zh) * | 2002-10-09 | 2005-10-26 | 辉瑞产品公司 | 用于治疗神经变性疾病的噻唑化合物 |
AU2003288956A1 (en) | 2002-10-30 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
FR2850380B1 (fr) * | 2003-01-23 | 2006-07-07 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique |
JP2006182648A (ja) | 2003-04-08 | 2006-07-13 | Dai Ichi Seiyaku Co Ltd | 7員複素環誘導体 |
TW200519106A (en) * | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
CA2536253A1 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | Aminofurazan compounds useful as protein kinase inhibitors |
JP2007504255A (ja) * | 2003-09-06 | 2007-03-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atp結合カセットトランスポーターの調節因子 |
GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
GB0329275D0 (en) | 2003-12-18 | 2004-01-21 | Merck Sharp & Dohme | Therapeutic treatment |
ZA200605624B (en) | 2004-01-12 | 2007-11-28 | Applied Research Systems | Thiazole derivatives and use thereof |
JP2007517840A (ja) * | 2004-01-16 | 2007-07-05 | サノフイ−アベンテイス | アシルアミノチアゾール誘導体、それらの調製方法及び治療における該誘導体の使用 |
JP4813371B2 (ja) * | 2004-01-16 | 2011-11-09 | サノフイ−アベンテイス | アシルアミノチアゾール誘導体及びβ−アミロイド阻害剤としてのこれらの使用 |
US20070185152A1 (en) * | 2004-03-02 | 2007-08-09 | Smithkline Beecham Corporation | Inhibitors of akt activity |
RS50595B (sr) | 2004-03-23 | 2010-05-07 | Pfizer Products Incorporated | Jedinjenja imidazola za lečenje neurodegenerativnih poremećaja |
BRPI0508230A (pt) * | 2004-03-30 | 2007-07-17 | Chiron Corp | derivados de tiofeno substituìdo como agentes anti-cáncer |
AU2005247871A1 (en) * | 2004-04-27 | 2005-12-08 | Research Development Foundation | Antagonism of TGF-beta superfamily receptor signaling |
WO2005113579A1 (en) * | 2004-05-21 | 2005-12-01 | Mpex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors and methods of treating bacterial infections |
GB0411791D0 (en) | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
AU2005272815A1 (en) | 2004-08-13 | 2006-02-23 | Genentech, Inc. | Thiazole based inhibitors of ATP-utilizing enzymes |
WO2006038734A1 (en) * | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
US7354944B2 (en) * | 2004-10-18 | 2008-04-08 | Amgen Inc. | Thiadiazole compounds and methods of use |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
KR100917511B1 (ko) * | 2005-02-28 | 2009-09-16 | 니뽄 다바코 산교 가부시키가이샤 | Syk 저해 활성을 갖는 신규한 아미노피리딘 화합물 |
EP2314574A1 (en) * | 2005-06-17 | 2011-04-27 | Apogee Biothechnology Corporation | Sphingosine kinase inhibitors |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
DE102005048072A1 (de) | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
WO2007066805A1 (ja) | 2005-12-09 | 2007-06-14 | Meiji Seika Kaisha, Ltd. | リンコマイシン誘導体およびこれを有効成分とする抗菌剤 |
ZA200805227B (en) | 2005-12-12 | 2009-11-25 | Genelabs Tech Inc | N-(5-memebered heteroarmatic ring)-amido anti-viral compounds |
JP2009528266A (ja) | 2006-01-18 | 2009-08-06 | シェーリング コーポレイション | カンナビノイド受容体修飾因子 |
CN101370799B (zh) | 2006-01-18 | 2012-09-05 | 霍夫曼-拉罗奇有限公司 | 作为mdm2抑制剂的顺-4,5-二芳基-2-杂环-咪唑啉 |
CA2636077C (en) | 2006-01-18 | 2012-01-03 | Amgen Inc. | Thiazole compounds as protein kinase b (pkb) inhibitors |
US20080242694A1 (en) | 2006-09-18 | 2008-10-02 | D Sidocky Neil R | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith |
-
2007
- 2007-01-11 CA CA2636077A patent/CA2636077C/en not_active Expired - Fee Related
- 2007-01-11 BR BRPI0706621-0A patent/BRPI0706621A2/pt not_active IP Right Cessation
- 2007-01-11 CN CNA2007800097081A patent/CN101421265A/zh active Pending
- 2007-01-11 ES ES07718125T patent/ES2389062T3/es active Active
- 2007-01-11 US US11/652,728 patent/US7514566B2/en active Active
- 2007-01-11 EA EA200801716A patent/EA200801716A1/ru unknown
- 2007-01-11 WO PCT/US2007/000871 patent/WO2007084391A2/en active Application Filing
- 2007-01-11 EP EP07718125A patent/EP1981884B1/en active Active
- 2007-01-11 KR KR1020087019941A patent/KR20080091369A/ko not_active Application Discontinuation
- 2007-01-11 JP JP2008551297A patent/JP5199885B2/ja not_active Expired - Fee Related
- 2007-01-11 MY MYPI20082598A patent/MY149143A/en unknown
- 2007-01-11 AU AU2007207743A patent/AU2007207743B2/en not_active Ceased
- 2007-01-17 TW TW096101796A patent/TW200738657A/zh unknown
- 2007-01-18 UY UY30098A patent/UY30098A1/es not_active Application Discontinuation
- 2007-01-18 AR ARP070100212A patent/AR059064A1/es unknown
- 2007-01-18 PE PE2007000057A patent/PE20071114A1/es not_active Application Discontinuation
- 2007-11-01 UA UAA200810455A patent/UA91895C2/ru unknown
-
2008
- 2008-07-10 IL IL192751A patent/IL192751A0/en unknown
- 2008-07-23 ZA ZA200806386A patent/ZA200806386B/xx unknown
- 2008-08-18 CR CR10211A patent/CR10211A/es not_active Application Discontinuation
- 2008-08-18 NO NO20083572A patent/NO20083572L/no not_active Application Discontinuation
-
2009
- 2009-02-11 US US12/378,195 patent/US8084479B2/en active Active
Non-Patent Citations (1)
Title |
---|
None |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700636B2 (en) | 2004-10-18 | 2010-04-20 | Amgen Inc. | Thiadiazole compounds and methods of use |
US7919514B2 (en) | 2004-10-18 | 2011-04-05 | Amgen Inc. | Thiadiazole compounds and methods of use |
US8084479B2 (en) | 2006-01-18 | 2011-12-27 | Amgen Inc. | Thiazole compounds and methods of use |
US8501747B2 (en) | 2007-02-13 | 2013-08-06 | Merck Sharp & Dohme Corp. | Functionally selective alpha2C adrenoreceptor agonists |
JP2010518159A (ja) * | 2007-02-13 | 2010-05-27 | シェーリング コーポレイション | 機能選択性α2Cアドレナリン受容体アゴニスト |
WO2008100456A3 (en) * | 2007-02-13 | 2008-11-06 | Schering Corp | Functionally selective alpha2c adrenoreceptor agonists |
WO2008100456A2 (en) * | 2007-02-13 | 2008-08-21 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
WO2009011880A2 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
WO2009011880A3 (en) * | 2007-07-17 | 2009-04-02 | Amgen Inc | Heterocyclic modulators of pkb |
US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
US7919504B2 (en) | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
AU2009244491B2 (en) * | 2008-05-06 | 2014-08-07 | Novartis Ag | Benzene sulfonamide thiazole and oxazole compounds |
WO2009137391A3 (en) * | 2008-05-06 | 2009-12-30 | Smithkline Beecham Corporation | Benzene sulfonamide thiazole and oxazole compounds |
US9233956B2 (en) | 2008-05-06 | 2016-01-12 | Novartis Ag | Benzene sulfonamide thiazole and oxazole compounds |
KR101628746B1 (ko) | 2008-05-06 | 2016-06-13 | 노바르티스 아게 | 벤젠 설폰아미드 티아졸 및 옥사졸 화합물 |
US8642759B2 (en) | 2008-05-06 | 2014-02-04 | Glaxosmithkline Llc | Benzene sulfonamide thiazole and oxazole compounds |
CN102083312A (zh) * | 2008-05-06 | 2011-06-01 | 葛兰素史密丝克莱恩有限责任公司 | 苯磺酰胺噻唑和噁唑化合物 |
US7994185B2 (en) | 2008-05-06 | 2011-08-09 | Glaxo Smith Kline LLC | Benzene sulfonamide thiazole and oxazole compounds |
KR20110013456A (ko) * | 2008-05-06 | 2011-02-09 | 글락소스미스클라인 엘엘씨 | 벤젠 설폰아미드 티아졸 및 옥사졸 화합물 |
US8415345B2 (en) | 2008-05-06 | 2013-04-09 | Glaxo SmithKline LLC | Benzene sulfonamide thiazole and oxazole compounds |
EA019349B1 (ru) * | 2008-05-06 | 2014-03-31 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Соединения бензолсульфонамидтиазола и оксазола |
EP2326631A4 (en) * | 2008-08-18 | 2012-03-21 | Univ Yale | MODULATORS OF MIF |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
EP2326631A2 (en) * | 2008-08-18 | 2011-06-01 | Yale University | Mif modulators |
US10202343B2 (en) | 2008-08-18 | 2019-02-12 | Yale University | MIF modulators |
US11584717B2 (en) | 2008-08-18 | 2023-02-21 | Yale University | MIF modulators |
CN106243100A (zh) * | 2008-10-10 | 2016-12-21 | Vm生物医药公司 | 治疗酒精使用障碍,疼痛和其他疾病的药物组合与方法 |
CN106243100B (zh) * | 2008-10-10 | 2019-04-09 | Vm生物医药公司 | 治疗酒精使用障碍,疼痛和其他疾病的药物组合与方法 |
WO2010083246A1 (en) * | 2009-01-15 | 2010-07-22 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
US10023537B2 (en) | 2009-06-25 | 2018-07-17 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
US11518745B2 (en) | 2009-06-25 | 2022-12-06 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
US10112903B2 (en) | 2009-06-25 | 2018-10-30 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
EP2445502B1 (en) * | 2009-06-25 | 2017-06-21 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
US10351529B2 (en) | 2009-06-25 | 2019-07-16 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
US10822306B2 (en) | 2009-06-25 | 2020-11-03 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
US8835450B2 (en) | 2009-10-08 | 2014-09-16 | Glaxosmithkline Llc | Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer |
AU2010303364B2 (en) * | 2009-10-08 | 2013-09-19 | Novartis Ag | Combination |
EA022982B1 (ru) * | 2009-10-08 | 2016-04-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Комбинация для лечения рака или предраковых синдромов |
EA023018B1 (ru) * | 2009-10-08 | 2016-04-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Комбинация для лечения рака или предраковых синдромов |
AU2010303363B2 (en) * | 2009-10-08 | 2013-09-05 | Novartis Ag | Combination |
US9402846B2 (en) | 2009-10-08 | 2016-08-02 | Novartis Ag | Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer |
WO2011044415A1 (en) * | 2009-10-08 | 2011-04-14 | Glaxosmithkline Llc | Combination |
US8796298B2 (en) | 2009-10-08 | 2014-08-05 | Glaxosmithkline Llc | Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer |
WO2011044414A1 (en) * | 2009-10-08 | 2011-04-14 | Glaxosmithkline Llc | Combination |
EA020965B1 (ru) * | 2009-10-12 | 2015-03-31 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Способ и фармацевтическая комбинация для лечения рака |
AU2010307043C1 (en) * | 2009-10-12 | 2014-03-13 | Glaxosmithkline Llc | Combination |
AU2010307043B2 (en) * | 2009-10-12 | 2013-10-31 | Glaxosmithkline Llc | Combination |
WO2011046894A1 (en) * | 2009-10-12 | 2011-04-21 | Glaxosmithkline Llc | Combination |
WO2011115071A1 (ja) * | 2010-03-15 | 2011-09-22 | 国立大学法人広島大学 | チエノピリジン誘導体及びその製造方法、並びにそれを用いた有機半導体デバイス |
CN102884068A (zh) * | 2010-03-15 | 2013-01-16 | 国立大学法人广岛大学 | 噻吩并吡啶衍生物及其制备方法、以及使用该衍生物的有机半导体器件 |
JP2013525303A (ja) * | 2010-04-16 | 2013-06-20 | アッヴィ・インコーポレイテッド | フタラジン−(2h)−オン系キナーゼ阻害薬 |
WO2011130921A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
EP2832731A4 (en) * | 2012-03-27 | 2015-08-19 | Shionogi & Co | AROMATIC HETEROCYCLIC CHAIN 5-CORE DERIVED DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY |
US9499533B2 (en) | 2012-03-27 | 2016-11-22 | Shionogi & Co., Ltd. | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity |
WO2013173382A1 (en) | 2012-05-15 | 2013-11-21 | Amgen Inc. | Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein |
JP2018510857A (ja) * | 2015-03-02 | 2018-04-19 | ライジェル ファーマシューティカルズ, インコーポレイテッド | TGF−β阻害剤 |
US11566003B2 (en) | 2017-03-30 | 2023-01-31 | Genentech, Inc. | Isoquinolines as inhibitors of HPK1 |
US11479770B2 (en) | 2017-10-05 | 2022-10-25 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of DUX4 |
US11291659B2 (en) | 2017-10-05 | 2022-04-05 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US10537560B2 (en) | 2017-10-05 | 2020-01-21 | Fulcrum Therapeutics. Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
CN111603466B (zh) * | 2020-06-29 | 2022-07-22 | 江南大学 | 一种乙酮类化合物在制备治疗肿瘤药物中的应用 |
CN111603466A (zh) * | 2020-06-29 | 2020-09-01 | 江南大学 | 一种乙酮类化合物在制备治疗肿瘤药物中的应用 |
CN114014787A (zh) * | 2022-01-10 | 2022-02-08 | 苏州开元民生科技股份有限公司 | 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法 |
Also Published As
Publication number | Publication date |
---|---|
PE20071114A1 (es) | 2008-01-10 |
CN101421265A (zh) | 2009-04-29 |
US20070173506A1 (en) | 2007-07-26 |
IL192751A0 (en) | 2009-02-11 |
EP1981884B1 (en) | 2012-06-13 |
AU2007207743B2 (en) | 2010-07-08 |
ZA200806386B (en) | 2009-11-25 |
ES2389062T3 (es) | 2012-10-22 |
US8084479B2 (en) | 2011-12-27 |
JP5199885B2 (ja) | 2013-05-15 |
AU2007207743A1 (en) | 2007-07-26 |
UA91895C2 (en) | 2010-09-10 |
WO2007084391A3 (en) | 2008-03-20 |
AR059064A1 (es) | 2008-03-12 |
EP1981884A2 (en) | 2008-10-22 |
US7514566B2 (en) | 2009-04-07 |
BRPI0706621A2 (pt) | 2011-04-05 |
MY149143A (en) | 2013-07-15 |
CA2636077C (en) | 2012-01-03 |
EA200801716A1 (ru) | 2009-04-28 |
TW200738657A (en) | 2007-10-16 |
UY30098A1 (es) | 2007-10-31 |
NO20083572L (no) | 2008-10-17 |
KR20080091369A (ko) | 2008-10-10 |
CA2636077A1 (en) | 2007-07-26 |
JP2009525960A (ja) | 2009-07-16 |
CR10211A (es) | 2008-10-03 |
US20090270445A1 (en) | 2009-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1981884B1 (en) | Thiazole compounds as protein kinase b (pkb) inhibitors | |
US7919504B2 (en) | Thiadiazole modulators of PKB | |
US7897619B2 (en) | Heterocyclic modulators of PKB | |
US20110263647A1 (en) | Fluoroisoquinoline substituted thiazole compounds and methods of use | |
ES2538581T3 (es) | Compuestos de pirimidina que inhiben la quinasa de linfoma anaplásico | |
US6822097B1 (en) | Compounds and methods of uses | |
US9505749B2 (en) | Quinazolinone compounds and derivatives thereof | |
WO2013134079A1 (en) | Oxazolidinone compounds and derivatives thereof | |
WO2003101985A1 (en) | 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders | |
US20040147561A1 (en) | Pyrid-2-one derivatives and methods of use | |
CA2486530A1 (en) | 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2636077 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008071135 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501616 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 569706 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 192751 Country of ref document: IL Ref document number: 2007207743 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/009048 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007718125 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008551297 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3974/CHENP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2007207743 Country of ref document: AU Date of ref document: 20070111 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087019941 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2008-010211 Country of ref document: CR Ref document number: 200801716 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780009708.1 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: PI0706621 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080718 |